{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:02:10Z","timestamp":1767772930273,"version":"build-2065373602"},"reference-count":55,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007632","name":"Changhua Christian Hospital","doi-asserted-by":"publisher","award":["109-CCH-PRJ-117"],"award-info":[{"award-number":["109-CCH-PRJ-117"]}],"id":[{"id":"10.13039\/501100007632","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>A false negative can happen in many kinds of medical tests, regardless of whether they are screening or diagnostic in nature. However, it inevitably poses serious concerns especially in a prenatal setting because its sequelae can mark the birth of an affected child beyond expectation. False negatives are not a new thing because of emerging new tests in the field of reproductive, especially prenatal, genetics but has occurred throughout the evolution of prenatal screening and diagnosis programs. In this paper we aim to discuss the basic differences between screening and diagnosis, the trade-offs and the choices, and also shed light on the crucial points clinicians need to know and be aware of so that a quality service can be provided in a coherent and sensible way to patients so that vital issues related to a false negative result can be appropriately comprehended by all parties.<\/jats:p>","DOI":"10.3390\/diagnostics11050888","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T12:19:57Z","timestamp":1621253997000},"page":"888","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Understanding False Negative in Prenatal Testing"],"prefix":"10.3390","volume":"11","author":[{"given":"Mark I.","family":"Evans","sequence":"first","affiliation":[{"name":"Fetal Medicine Foundation of America, Icahn School of Medicine at Mt. Sinai, New York, NY 10029, USA"},{"name":"Department of Obstetrics & Gynecology, Icahn School of Medicine at Mt. Sinai, New York, NY 10029, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5076-2917","authenticated-orcid":false,"given":"Ming","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Genomic Medicine, Changhua Christian Hospital, Changhua 50046, Taiwan"},{"name":"Department of Obstetrics and Gynecology, National Taiwan University Hospital, College of Medicine, Taipei 10041, Taiwan"},{"name":"Department of Biomedical Science, Dayeh University, Changhua 51591, Taiwan"},{"name":"Department of Medical Sciences, National Tsing Hua University, Hsinchu 30013, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Britt","sequence":"additional","affiliation":[{"name":"Fetal Medicine Foundation of America, Icahn School of Medicine at Mt. Sinai, New York, NY 10029, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,17]]},"reference":[{"key":"ref_1","unstructured":"Galen, R.S., and Gambino, S.R. (1975). Beyond Normality: The Predictive Value and Efficiency of Medical Diagnoses, Wiley."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00003081-200209000-00009","article-title":"Principles of Screening","volume":"45","author":"Evans","year":"2002","journal-title":"Clin. Obstet. Gynecol."},{"key":"ref_3","first-page":"10","article-title":"Re-conceptualizing fetal monitoring","volume":"1","author":"Evans","year":"2019","journal-title":"Eur. J. Gynecol. Obstet."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1001\/jama.2016.11139","article-title":"Modeled fetal risk of genetic diseases identified by expanded carrier screening","volume":"316","author":"Haque","year":"2016","journal-title":"JAMA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJMoa1704559","article-title":"Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia","volume":"377","author":"Rolnik","year":"2017","journal-title":"NEJM"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/pd.5495","article-title":"Pandora\u2019s pregnancy: NIPT, CMA, and genetic sequencing\u2014A new ear for prenatal genetic testing","volume":"39","author":"Rza","year":"2019","journal-title":"Prenat. Diagn."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Committee on Practice Bulletins-Gynecology (2017). Practice Bulletin number 179: Breast Cancer risk assessment and screening in average risk women. Obstet. Gynecol., 130, e1\u2013e16.","DOI":"10.1097\/AOG.0000000000002158"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.bulcan.2018.10.009","article-title":"Lynch syndrome: What is new?","volume":"106","author":"Pellat","year":"2019","journal-title":"Bull. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ogc.2018.09.002","article-title":"Cancer screening and prevention highlights in gynecologic cancer","volume":"46","author":"Staples","year":"2019","journal-title":"Obstet. Gynecol. Clin. N. Am."},{"key":"ref_10","unstructured":"Wilson, J.M.G., and Jungner, G. (1968). Principles and Practice of Screening for Disease, World Health Organization."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Saito, T., and Rehmsmeier, M. (2015). The precision recall plot is more informative than the ROC plot when evaluating classifiers on imbalanced datasets. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0118432"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S1525-1578(10)60484-9","article-title":"Bayesian analysis and risk assessment in genetic counseling and testing","volume":"6","author":"Ogino","year":"2004","journal-title":"J. Med. Diagn."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/0002-9378(88)90583-2","article-title":"Determinants of altered anxiety following abnormal maternal serum alpha-fetoprotein screening","volume":"159","author":"Evans","year":"1988","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ajog.2016.04.029","article-title":"Noninvasive prenatal screening or advanced diagnostic testing: Caveat emptor","volume":"215","author":"Evans","year":"2016","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/pd.5275","article-title":"The epidemic of abnormal copy number variant cases missed because of reliance upon noninvasive prenatal screening","volume":"38","author":"Evans","year":"2018","journal-title":"Prenat. Diagn."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/pd.5226","article-title":"The price of abandoning diagnostic testing for cell-free fetal DNA screening","volume":"38","author":"Evans","year":"2018","journal-title":"Prenat. Diagn."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000020893","article-title":"Participation in prenatal screening tests and intentions concerning selective termination in Finnish medical care","volume":"14","author":"Santalahti","year":"1999","journal-title":"Fetal. Diagn. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/(SICI)1096-8628(19980806)78:5<433::AID-AJMG8>3.0.CO;2-M","article-title":"Characteristics of women who refuse an offer of prenatal diagnosis: Data from the California maternal serum alpha fetoprotein blood test experience","volume":"78","author":"Press","year":"1998","journal-title":"Am. J. Med. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"629","DOI":"10.18865\/ed.29.S3.629","article-title":"Two threats to precision medical equity","volume":"29","author":"Matthew","year":"2019","journal-title":"Ethn. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1089\/jwh.1998.7.817","article-title":"The long view: How genetic discoveries will aid health care reform","volume":"7","author":"Fletcher","year":"1998","journal-title":"J. Women\u2019s Health"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Duster, T. (2003). Backdoor to Eugenics, Routledge. [2nd ed.].","DOI":"10.4324\/9780203426951"},{"key":"ref_22","first-page":"685","article-title":"Amniotic fluid alpha-fetoprotein measurement in antenatal diagnosis of anencephaly and open spina bifida in early pregnancy","volume":"1","author":"Wald","year":"1979","journal-title":"Lancet"},{"key":"ref_23","unstructured":"Gastel, B., Haddow, J.E., Fletcher, J.C., and Neale, A. (1980). Maternal Serum Alpha-Fetoprotein: Issues in the Prenatal Screening and Diagnosis of Neural Tube Defects."},{"key":"ref_24","first-page":"189","article-title":"Genetic epidemiology of neural tube defects","volume":"10","author":"Lupo","year":"2017","journal-title":"J. Pediatr. Rehabil. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(73)92592-0","article-title":"Prenatal diagnosis of anencephaly through maternal serum alpha-fetoprotein measurements","volume":"2","author":"Brock","year":"1973","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1037\/0003-066X.34.10.844","article-title":"Contexts of child rearing: Problems and prospects","volume":"34","author":"Bronfenbrenner","year":"1979","journal-title":"Am. Psychol."},{"key":"ref_27","first-page":"342","article-title":"Wide variation in maternal serum alpha-fetoprotein (MSAFP) reports in one metropolitan area: Concerns for the quality of prenatal testing","volume":"72","author":"Evans","year":"1988","journal-title":"Obstet. Gynecol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/BF02075880","article-title":"Interlaboratory variation in the prenatal screening for neural tube closing defects","volume":"29","author":"Braoudakis","year":"1984","journal-title":"Soz. Praventivmed."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/0002-9378(87)90045-7","article-title":"Maternal serum alpha-fetoprotein screening: II. Pitfalls in low volume decentralized laboratory performance","volume":"156","author":"Macri","year":"1987","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/S0002-9378(13)90033-8","article-title":"Risk of anomalies as a function of level of elevated maternal serum alpha-fetoprotein","volume":"171","author":"Reichler","year":"1994","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_31","first-page":"543","article-title":"Combined ultrasonography and amniocentesis for pregnant women with elevated maternal serum alpha-fetoprotein: Revising the risk estimate","volume":"35","author":"Schell","year":"1990","journal-title":"J. Reprod. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ajog.2006.08.001","article-title":"Meta-Analysis of first trimester Down Syndrome screening studies: Free beta hCG significantly outperforms intact hCG in a multi-marker protocol","volume":"196","author":"Evans","year":"2007","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000324320","article-title":"Turning the pyramid of prenatal care","volume":"29","author":"Nicolaides","year":"2011","journal-title":"Fetal. Diagn. Ther."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/AOG.0b013e3181f23ae3","article-title":"Undermeasurement of nuchal translucencies: Implications for screening","volume":"116","author":"Evans","year":"2010","journal-title":"Obstet. Gynecol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/uog.9023","article-title":"Impact of nuchal translucency credentialing by the FMF, the NTQR or both on screening distributions and performance","volume":"39","author":"Evans","year":"2012","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/pd.2769","article-title":"Performance Adjusted Risks: A method to improve the quality of algorithm performance while allowing all to play","volume":"31","author":"Evans","year":"2011","journal-title":"Prenat. Diagn."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.ajog.2007.11.056","article-title":"Overcoming Militant Mediocrity","volume":"198","author":"Evans","year":"2008","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/uog.14693","article-title":"Cell-free fetal DNA screening in the USA: A cost analysis of screening strategies","volume":"45","author":"Evans","year":"2015","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.ajhg.2019.10.005","article-title":"TRIDENT 2: National implementation of genome wide non invasive prenatal testing as a first tier screening test in the Netherlands","volume":"105","author":"Sistermans","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/medethics-2019-105675","article-title":"Should pregnant women be charged for non-invasive prenatal screening? Implications for reproductive autonomy and equal access","volume":"46","author":"Bunnik","year":"2020","journal-title":"J. Med. Ethics"},{"key":"ref_41","unstructured":"Evans, M.I., Johnson, M.P., Yaron, Y., and Drugan, A. (2006). Psychosocial issues in Prenatal Diagnosis. Prenatal Diagnosis, McGraw Hill Professional."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1055\/s-0038-1637764","article-title":"Predicting the future: Delivery room planning of congenital heart disease diagnosed by fetal echocardiography","volume":"35","author":"Donofrio","year":"2018","journal-title":"Am. J. Perinatol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Evans, I.M., and Hanft, R. (1997). The Introduction of New Technologies, ACOG Clinical Seminars, ACOG.","DOI":"10.1016\/S1085-6862(97)00035-6"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Cohen, A.B., and Hanft, R.S. (2004). Technology in American Health Care: Policy Directions for Effective Evaluation and Management, University of Michigan Press.","DOI":"10.3998\/mpub.17780"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/1096-8628(20000828)93:5<410::AID-AJMG12>3.0.CO;2-F","article-title":"Determinants of parental decisions after prenatal diagnosis of Down syndrome: Bringing in context","volume":"93","author":"Britt","year":"2000","journal-title":"Am. J. Med. Genet."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1469-0705.2002.00766.x","article-title":"Devastation and relief: Conflicting meanings in discovering fetal anomalies","volume":"20","author":"Britt","year":"2002","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/pd.5620","article-title":"Fetal fraction and noninvasive prenatal testing: What clinicians need to know","volume":"40","author":"Hui","year":"2020","journal-title":"Prenat. Diagn."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/s41436-019-0748-y","article-title":"Non-invasive prenatal diagnosis by genome-wide haplotyping of cell-free plasma DNA","volume":"22","author":"Che","year":"2020","journal-title":"Genet. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.ajhg.2019.11.004","article-title":"Validation study for single circulating trophoblast genetic testing as a form of noninvasive prenatal diagnosis","volume":"105","author":"Vossaert","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1007\/s43032-020-00243-1","article-title":"The number of circulating fetal extravillous trophoblasts varies from gestational week 6 to 20","volume":"27","author":"Ravn","year":"2020","journal-title":"Reprod. Sci."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/pd.347","article-title":"Fetal gender and aneuploidy detection using fetal cells in maternal blood: Analysis of NIFTY I data. National Institute of Child Health and Development Fetal Cell Isolation Study","volume":"22","author":"Bianchi","year":"2002","journal-title":"Prenat. Diagn."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Jou, H.J., Chou, L.Y., Chang, W.C., Ho, H.C., Zhang, W.T., Ling, P.Y., Tsai, K.H., Chen, T.H., Chen, S.H., and Lo, P.H. (2021). A novel automatic platform based on nanostructured microfluidic chip for isolating and identification of circulating tumor cells. Micromachines, 12.","DOI":"10.21203\/rs.3.rs-226461\/v1"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13039-017-0343-3","article-title":"Noninvasive prenatal diagnosis of fetal aneuploidy by circulating fetal nucleated red blood cells and extravillous trophoblasts using silicon-based nanostructured microfluidics","volume":"2","author":"Huang","year":"2017","journal-title":"Mol. Cytogenet."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Ma, G.C., Lin, W.H., Huang, C.E., Chang, T.Y., Liu, C.Y., Yang, Y.J., Lee, M.H., Wu, W.J., Chang, Y.S., and Chen, M. (2019). A silicon-based coral-like nanostructured microfluidics to isolate rare cells in human circulation: Validation by SK-BR-3 cancer cell line and its utility in fetal nucleated red blood cells. Micromachines, 10.","DOI":"10.3390\/mi10020132"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1038\/ejhg.2015.57","article-title":"Non-invasive prenatal testing for aneuploidy and beyond: Challenges of responsible innovation in prenatal screening","volume":"23","author":"Dondorp","year":"2015","journal-title":"Eur. J. Hum. Genet."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/11\/5\/888\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:02:43Z","timestamp":1760162563000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/11\/5\/888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,17]]},"references-count":55,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["diagnostics11050888"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics11050888","relation":{},"ISSN":["2075-4418"],"issn-type":[{"type":"electronic","value":"2075-4418"}],"subject":[],"published":{"date-parts":[[2021,5,17]]}}}